Form D · Biotechnology

Eikon Therapeutics, Inc.

Hayward, CA · CIK 0001861123

Offering snapshot reported Feb 28, 2025 · SEC filing

Reported sold
$351M
Offering amount: $400M
Investors reported
27
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Feb 14, 2025
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Feb 28, 2025Initial$350,700,037No comparison27SEC filing
Jun 1, 2023Initial$140,759,782No comparison21SEC filing
Jan 6, 2022Initial$517,764,785No comparison43SEC filing
May 13, 2021Initial$102,537,782No comparison12SEC filing

Offering details

Securities
Equity, Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-539574

Source: Form D, filed Feb 28, 2025. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Dan Anderson Executive
Roy Banes Executive
Dror Berman Director
Russ Berman Executive
Alfred Bowie Executive
Leon Chen Director
Kenneth Frazier Director
Adam Goulburn Director
Barbara Howes Executive
Robbie Huffines Director
Ashish Kheterpal Executive
Roger M. Perlmutter Director, Executive
James Tananbaum Director
Benjamin Thorner Executive
Robin Washington Director
Josh Wolfe Director
Joshua Wolfe Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
3929 Point Eden Way
Hayward, CA, 94545